BUZZ-Grifols beats H1 estimates, shares jump

Reuters

Jul 30, 2025

BUZZ-Grifols beats H1 estimates, shares jump

** Shares of Grifols GRLS.MC jump 9% after the Spanish drugmaker reported H1 results ahead of expectations, boosted by 'strong momentum' in immunoglobulin and proteins business

** The company booked a net profit of 177 million euros ($204.63 million), up 392% year-on-year, well above 141.1 mln euros expected by Bloomberg consensus, Capital Market says

** It also posted a 10.7% rise year-on-year in its adjusted EBITDA to 876 mln euros, up from 858.1 mln euros forecasted by Bloomberg

** Immunoglobulin revenues grew by 12.0% cc in the second quarter of the year

** 'We consider Grifols' immunoglobulins revenue performance as a positive read-through for CSL as it highlights ongoing strength in the Ig market,' RBC analysts say

** Share price is at its highest in 1.6 years, outperforming the IBEX35 index .IBEX, which falls 0.6%

($1 = 0.8650 euros)

(Reporting by Mireia Merino)

((Mireia.Merino@thomsonreuters.com; Reuters Messaging: mireia.merino.thomsonreuters.com@reuters.net))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2555886015"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555886015\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555886015?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-30 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555886015","market":"nz","top_or_hot":-1,"title":"BUZZ-Grifols beats H1 estimates, shares jump","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Grifols beats H1 estimates, shares jump</title></head><body><p>** Shares of Grifols <span>GRLS.MC</span> jump 9% after the Spanish drugmaker reported <span>H1 results</span> ahead of expectations, boosted by 'strong momentum' in immunoglobulin and proteins business</p><p>** The company booked a net profit of 177 million euros  ($204.63 million), up 392% year-on-year, well above 141.1 mln euros expected by Bloomberg consensus, Capital Market says</p><p>** It also posted a 10.7% rise year-on-year in its adjusted EBITDA to 876 mln euros, up from 858.1 mln euros forecasted by Bloomberg</p><p>** Immunoglobulin revenues grew by 12.0% cc in the second quarter of the year</p><p>** 'We consider Grifols' immunoglobulins revenue performance as a positive read-through for CSL as it highlights ongoing strength in the Ig market,' RBC analysts say</p><p>** Share price is at its highest in 1.6 years, outperforming the IBEX35 index <span>.IBEX</span>, which falls 0.6% </p><p>($1 = 0.8650 euros)</p><p> (Reporting by Mireia Merino)</p><p> ((Mireia.Merino@thomsonreuters.com; Reuters Messaging: mireia.merino.thomsonreuters.com@reuters.net))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Grifols beats H1 estimates, shares jump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Grifols beats H1 estimates, shares jump\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-30 15:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Grifols beats H1 estimates, shares jump</title></head><body><p>** Shares of Grifols <span>GRLS.MC</span> jump 9% after the Spanish drugmaker reported <span>H1 results</span> ahead of expectations, boosted by 'strong momentum' in immunoglobulin and proteins business</p><p>** The company booked a net profit of 177 million euros  ($204.63 million), up 392% year-on-year, well above 141.1 mln euros expected by Bloomberg consensus, Capital Market says</p><p>** It also posted a 10.7% rise year-on-year in its adjusted EBITDA to 876 mln euros, up from 858.1 mln euros forecasted by Bloomberg</p><p>** Immunoglobulin revenues grew by 12.0% cc in the second quarter of the year</p><p>** 'We consider Grifols' immunoglobulins revenue performance as a positive read-through for CSL as it highlights ongoing strength in the Ig market,' RBC analysts say</p><p>** Share price is at its highest in 1.6 years, outperforming the IBEX35 index <span>.IBEX</span>, which falls 0.6% </p><p>($1 = 0.8650 euros)</p><p> (Reporting by Mireia Merino)</p><p> ((Mireia.Merino@thomsonreuters.com; Reuters Messaging: mireia.merino.thomsonreuters.com@reuters.net))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nL1N3TR061:1","article_id":"2555886015","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555886015","pubTimestamp":1753861017,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Grifols beats H1 estimates, shares jump** Shares of Grifols GRLS.MC jump 9% after the Spanish drugmaker reported H1 results ahead of expectations, boosted by 'strong momentum' in immunoglobulin a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7511":"ESG概念","BK7508":"医药生物股","CSL.AU":"CSL LIMITED","BK7501":"新冠治疗股"},"translate_title":"BUZZ-Grifols上半年超出预期，股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9},"content_text":"BUZZ-Grifols beats H1 estimates, shares jump** Shares of Grifols GRLS.MC jump 9% after the Spanish drugmaker reported H1 results ahead of expectations, boosted by 'strong momentum' in immunoglobulin and proteins business** The company booked a net profit of 177 million euros  ($204.63 million), up 392% year-on-year, well above 141.1 mln euros expected by Bloomberg consensus, Capital Market says** It also posted a 10.7% rise year-on-year in its adjusted EBITDA to 876 mln euros, up from 858.1 mln euros forecasted by Bloomberg** Immunoglobulin revenues grew by 12.0% cc in the second quarter of the year** 'We consider Grifols' immunoglobulins revenue performance as a positive read-through for CSL as it highlights ongoing strength in the Ig market,' RBC analysts say** Share price is at its highest in 1.6 years, outperforming the IBEX35 index .IBEX, which falls 0.6% ($1 = 0.8650 euros) (Reporting by Mireia Merino) ((Mireia.Merino@thomsonreuters.com; Reuters Messaging: mireia.merino.thomsonreuters.com@reuters.net))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}